Aaron L Ellenbogen DO
Movement Disorder
Neurologist in Farmington, Michigan and is affiliated with multiple hospitals in the area, including Beaumont Hospital-Farmington Hills and Beaumont Hospital-Troy
Join to View Full Profile
28595 Orchard Lake RdSte 200Farmington Hills, MI 48334
Phone+1 248-553-0010
Fax+1 248-553-5957
Dr. Ellenbogen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Michigan State University College of Osteopathic MedicineClass of 1998
Certifications & Licensure
MI State License 1999 - 2028
AOA Board of Neurology and Psychiatry Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2013
Clinical Trials
- Study of SPARC1103 in Subjects With Spasticity Start of enrollment: 2014 Apr 21
- Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease Start of enrollment: 2014 Jun 01
- A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease Start of enrollment: 2016 Nov 30
Publications & Presentations
PubMed
- Long-Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN-Open-Label Study.Peter McAllister, Atul T Patel, Marta Banach, Aaron Ellenbogen, Jaroslaw Slawek
Movement Disorders Clinical Practice. 2025-11-01 - Reply to Trosch et al. Comment on "Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Ana...Khashayar Dashtipour, Han S Lee, Aaron Ellenbogen, Rashid Kazerooni, Todd M Gross
Toxins. 2025-04-11 - Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA.Aaron Ellenbogen, Robert A Hauser, Atul T Patel, Peter McAllister, Todd M Gross
Toxins. 2025-03-12
Journal Articles
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinica...Jankovic J1, Goodman I2, Safirstein B3, Marmon TK4, Schenk DB4, Koller M4, Zago W4, Ness DK4, Griffith SG5, Grundman M6,7, Soto J4, Ostrowitzki S8, Boess FG9, Martin-F..., JAMA Neurology, 10/2018
Press Mentions
Parkinson’s Risk Could Increase with Exposure to Common Chemical, Study SuggestsOctober 6th, 2025- Two Early Symptoms of Parkinson’s Disease Were Discovered. They Are Not ClearApril 4th, 2022
Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s PatientsSeptember 1st, 2017- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
